一心堂(002727.SZ)：擬與侯馬廣生堂及其股東就股權合作、共同實現臨汾市場快速發展等相關事宜簽訂股權合作協議
格隆匯12月27日丨一心堂(002727.SZ)公佈，根據公司的業務定位及發展規劃，公司於2020年12月25日在公司辦公室召開2020年第17次總裁辦公會，同意全資子公司山西鴻翔一心堂藥業有限公司(“山西一心堂”)以自有資金與侯馬市廣生堂連鎖藥店有限公司(“侯馬廣生堂”)及其股東就股權合作、共同實現臨汾市場快速發展等相關事宜簽訂股權合作協議。
此次合作，由山西一心堂(“甲方”)、匙鎖及朱琳(“乙方”)、侯馬廣生堂(“丙方”)三方在山西省臨汾市設立一家藥品零售連鎖企業(名稱暫定：山西一心堂廣生藥業有限公司，以下簡稱：合資公司)，合資公司註冊資本為750萬元，其中：甲方出資金額為15萬元，持股比例為2%；乙方出資金額為367.5萬元，持股比例為49%，丙方出資金額為367.5萬元，持股比例為49%。
合資公司在設立並取得公司營業執照、藥品經營許可證(含診所經營資質)之後，將丙方下屬的所有直營門店(共計44家)及其資產(以下簡稱：標的資產)並入合資公司，實現合資公司的正常經營。
丙方現有人員，在合資公司設立並將丙方資產並入的同時，與丙方解除勞動關係，與合資公司簽訂《勞動合同》。
在合資公司實現正常經營三個月，月含税銷售額達到420萬元、月淨利潤額達到25萬元(即：按年銷售換算為5,000萬元，年淨利潤為300萬元)時，甲方以不超過2082萬元受讓丙方所持有的合資公司49%股權，完成股權轉讓後，甲方持有合資公司51%的股權、乙方持有合資公司49%的股權。
如經審計及評估，合資公司不符上述業績指標(即：月銷售420萬元、月淨利潤25萬元)要求時，由合作三方協商對合資公司做估值調整，如協商不了，三方均可選擇終止本次合作且不承擔任何違約責任，同時，合資公司及本次合作涉及的所有藥店、診所等，均不得再使用標有“鴻翔”及“一心堂”的任何名稱、商標、字號。
通過設立新公司並完成股權合作，有利於擴大公司山西地區市場覆蓋範圍，加強鞏固山西市場，綜合提升公司競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
